Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America
This is Takeda’s fifth divestment over the last 12 months, contributing to the Company’s goal to divest approximately $10 billion USD in non-core assets

Takeda Pharmaceutical Company Limited   today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD.

The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth & Emerging Markets Business Unit.

“Takeda remains firmly committed to the emerging markets, and Latin America. This divestment enables us to focus our investments in these countries that center on our highly innovative medicines across Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience,” said Ricardo Marek, President, Growth & Emerging Markets Business Unit, Takeda, “Doing so will help meet the unmet needs of patients living with complex and rare conditions. At the same time, we are confident that Hypera Pharma is well placed to provide patients with uninterrupted access to the products they will acquire.”

This is Takeda’s fifth divestment over the last 12 months, contributing to the Company’s goal to divest approximately $10 billion USD in non-core assets. Takeda intends to use the proceeds from its divestitures to continue to reduce its debt and accelerate rapid deleveraging toward its target of 2x net debt/adjusted EBITDA within March 2022 – March 2024.

Takeda previously announced the sales of TachoSil® to Ethicon for $400 million USD in May 2019, Xiidra® to Novartis for up to $5.3 billion USD in July 2019, non-core assets in countries spanning Near East, Middle East and Africa to Acino for over $200 million USD in October 2019, and a portfolio of non-core assets in Russia, Georgia, and a number of Commonwealth of Independent States countries to STADA for $660 million USD in November 2019.


The non-core products in this latest transaction generated revenues of approximately $215 million USD in Fiscal Year 2018, driven by sales of key products such as Neosaldina®, Nesina®, and Dramin®.


While these trusted products continue to play important roles in meeting patient needs, they are not within Takeda's chosen business areas – Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – that are core to its global long-term strategy. Their divestment enables the Company to further focus on its key business areas through simplifying its portfolio.


“This announcement marks the latest step in Takeda’s strategy of streamlining and optimizing our portfolio while accelerating our deleveraging. By continuing to focus on our key business areas and pipeline of innovative medicines, we will strengthen our position as a R&D driven global biopharmaceutical leader and deliver enhanced value for patients and Takeda shareholders,” said Costa Saroukos, Chief Financial Officer, Takeda.


Transaction Details


Takeda has entered into an agreement to divest the rights, title, and interest to the products in a portfolio of approximately 18 select OTC and prescription pharmaceutical assets sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru - to Hypera Pharma for a total value of $825M USD.


Under the terms of the agreement, Takeda anticipates that approximately 300 commercial employees supporting the divested assets will be given the opportunity to transition over to Hypera Pharma at the close of this transaction.


Takeda and Hypera Pharma have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture these products and supply them to Hypera Pharma.


The transaction is expected to close in the second half of 2020, subject to the satisfaction of customary closing conditions. Until then, Takeda remains the owner of these products and responsible for ensuring patient access to them.

Tags : #Takeda #Disinvestment #Hyperapharma #825milliondollars

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026